Quick Answer
Kymera Therapeutics, Inc. reported Total Revenue of $39.21 million for fiscal year 2025.
Kymera Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $39.21M -16.7% |
$47.07M -40.1% |
$78.59M +67.8% |
$46.83M -35.7% |
$72.83M +114.0% |
$34.03M +1060.0% |
| Revenue (ASC 606) | $39.21M -16.7% |
$47.07M -40.1% |
$78.59M +67.8% |
$46.83M -35.7% |
$72.83M +114.0% |
$34.03M +1060.0% |
| Net Income | -$311.35M -39.1% |
-$223.86M -52.3% |
-$146.96M +5.1% |
-$154.81M -54.5% |
-$100.22M -119.8% |
-$45.59M -10.5% |
| Diluted EPS | -$3.69 -23.8% |
-$2.98 -18.3% |
-$2.52 +12.2% |
-$2.87 -37.3% |
-$2.09 +33.7% |
-$3.15 |
| Total Assets | $1.74B +78.2% |
$978.03M +69.9% |
$575.76M -4.5% |
$603.13M -0.5% |
$605.90M +24.4% |
$487.18M +317.5% |
| Cash and Equivalents | $357.01M +196.9% |
$120.26M +9.4% |
$109.97M +60.8% |
$68.39M +42.6% |
$47.98M +54.7% |
$31.00M -59.2% |
| Stockholders Equity | $1.58B +89.0% |
$835.62M +111.6% |
$394.97M -19.4% |
$490.15M +6.6% |
$459.64M +61.9% |
$283.89M +481.5% |
| R&D Expense | $316.57M +31.8% |
$240.25M +27.1% |
$189.08M +15.1% |
$164.25M +19.9% |
$137.02M +120.6% |
$62.10M +67.1% |
| Operating Income | -$349.40M -33.5% |
-$261.63M -58.1% |
-$165.53M -2.7% |
-$161.26M -60.4% |
-$100.53M -117.1% |
-$46.30M -9.7% |
| Shares Outstanding | 81.32M +25.3% |
64.89M +16.7% |
55.59M +1.0% |
55.04M +6.8% |
51.54M +15.9% |
44.48M +2205.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $2.76M | -26.1% | -75.9% |
| Revenue (ASC 606) | September 30, 2025 | $2.76M | -26.1% | -75.9% |
| Net Income | September 30, 2025 | -$82.17M | -31.5% | -7.3% |
| Diluted EPS | September 30, 2025 | -$0.94 | -14.6% | +1.1% |
| Total Assets | September 30, 2025 | $1.10B | +6.5% | -2.6% |
| Cash and Equivalents | September 30, 2025 | $112.95M | +2.0% | -66.4% |
| Stockholders Equity | September 30, 2025 | $946.26M | +6.0% | -2.6% |
| R&D Expense | September 30, 2025 | $74.09M | +22.7% | -5.5% |
| Operating Income | September 30, 2025 | -$92.52M | -28.3% | -9.4% |
| Shares Outstanding | September 30, 2025 | 71.74M | +10.8% | +1.7% |
- Kymera Therapeutics, Inc. reported Total Revenue of $39.21 million for fiscal year 2025.
- Kymera Therapeutics, Inc. showed a decrease of -16.7% in Total Revenue compared to the prior fiscal year.
- Kymera Therapeutics, Inc. reported Revenue (ASC 606) of $39.21 million for fiscal year 2025.
- Kymera Therapeutics, Inc. showed a decrease of -16.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Kymera Therapeutics, Inc. reported Net Income of -$311.35 million for fiscal year 2025.
- Kymera Therapeutics, Inc. showed a decrease of -39.1% in Net Income compared to the prior fiscal year.
- Kymera Therapeutics, Inc. reported Diluted EPS of $3.69 per share (loss) for fiscal year 2025.
- Kymera Therapeutics, Inc. showed a decrease of -23.8% in Diluted EPS compared to the prior fiscal year.
- Kymera Therapeutics, Inc. reported Total Assets of $1.74 billion for fiscal year 2025.
- Kymera Therapeutics, Inc. showed an increase of +78.2% in Total Assets compared to the prior fiscal year.
- Kymera Therapeutics, Inc. reported Cash and Equivalents of $357.01 million for fiscal year 2025.
- Kymera Therapeutics, Inc. showed an increase of +196.9% in Cash and Equivalents compared to the prior fiscal year.
- Kymera Therapeutics, Inc. reported Stockholders Equity of $1.58 billion for fiscal year 2025.
- Kymera Therapeutics, Inc. showed an increase of +89.0% in Stockholders Equity compared to the prior fiscal year.
- Kymera Therapeutics, Inc. reported R&D Expense of $316.57 million for fiscal year 2025.
- Kymera Therapeutics, Inc. showed an increase of +31.8% in R&D Expense compared to the prior fiscal year.
- Kymera Therapeutics, Inc. reported Operating Income of -$349.40 million for fiscal year 2025.
- Kymera Therapeutics, Inc. showed a decrease of -33.5% in Operating Income compared to the prior fiscal year.
- Kymera Therapeutics, Inc. reported Shares Outstanding of 81.32 million shares for fiscal year 2025.
- Kymera Therapeutics, Inc. showed an increase of +25.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: